GLP-1 Agonists Weight Loss Drugs Market Size, Share & Trends Analysis By Drugs (Semaglutide (Wegovy), Tirzepatide (Zepbound)), By Route of Administration, By Distribution Channel, By Region, And Segment forecasts, 2025 - 2030

https://marketpublishers.com/r/G555FE952545EN.html
Date: February 2025
Pages: 153
Price: US$ 5,950.00 (Single User License)
ID: G555FE952545EN

Abstracts

This report can be delivered to the clients within 3 Business Days

GLP-1 Agonists Weight Loss Drugs Market Growth & Trends
The global GLP-1 agonists weight loss drugs market size is anticipated t%li%reach USD 48.84 billion by 2030 and is projected t%li%grow at a CAGR of 18.54% from 2025 t%li%2030, according t%li%a new report by Grand View Research, Inc. The demand for GLP-1 Agonists in weight loss treatments, including Semaglutide (Wegovy), Liraglutide (Saxenda), and Tirzepatide (Zepbound), is fueling significant opportunities in the healthcare sector. These drugs, which have shown effective results in managing obesity and metabolic conditions, are driving market growth. Semaglutide (Wegovy) and Liraglutide (Saxenda) have already established themselves as reliable weight loss therapies, while Tirzepatide (Zepbound) is emerging as a promising option, showing even greater efficacy compared t%li%other drugs in its class. These therapies work by regulating appetite and improving insulin sensitivity, and with growing clinical evidence supporting their use, the acceptance of GLP-1 Agonists in obesity management is increasing.
The introduction of oral versions would not only make these therapies more accessible but als%li%broaden the patient base wh%li%prefer non-injection-based therapies.
Pharmacies are playing an increasingly important role in the distribution of GLP-1 Agonists. Retail pharmacies, in particular, are gaining traction in fulfilling prescriptions for Wegovy and Saxenda, providing not only access t%li%the medications but als%li%patient education and ongoing support for those managing obesity. Retail

+357 96 030922
info@marketpublishers.com

pharmacies’ ability t%li%offer convenient medication refills and counseling services makes them crucial in supporting the long-term management of weight loss. While hospital pharmacies are still key players, especially when patients start treatment and require close monitoring, retail pharmacies are taking on a more significant role as patients transition t%li%long-term care. Hospital pharmacies are important during the initial stages of therapy, where medical supervision is critical, but as patients stabilize and progress with treatment, they often shift t%li%retail or specialty pharmacies. These pharmacies play a vital role in providing continued access t%li%therapy and offering specialized services.

Specialty pharmacies and online pharmacies are als%li%becoming more involved in the distribution of GLP-1 Agonists weight loss drugs. These pharmacies can offer tailored services, such as home delivery and personalized medication counseling, which can be particularly beneficial for patients on long-term treatment regimens. By expanding their role, they provide added convenience and support for patients needing consistent access t%li%weight loss therapies.

The growing focus on combating obesity, one of the leading public health challenges, is driving the expansion of the GLP-1 agonists weight loss drug industry. With increasing recognition of the long-term health risks associated with obesity, such as type 2 diabetes, cardiovascular disease, and sleep apnea, there is a rising demand for effective treatments. Tirzepatide's novel mechanism of action, which targets both GLP-1 and GIP receptors, is attracting considerable attention for its superior efficacy and could further boost demand for GLP-1 Agonists.

As the demand for these medications rises, challenges will emerge, particularly in the areas of drug distribution and supply chain management. Ensuring that injectable therapies are consistently available will require robust cold chain logistics and increased focus on patient education t%li%optimize the use of the drugs. Moreover, the development of oral formulations represents a significant opportunity t%li%improve accessibility and adherence, providing a new avenue for pharmaceutical companies t%li%cater t%li%a broader patient population.

GLP-1 Agonists Weight Loss Drugs Market Report Highlights

- Based on drug, the semaglutide (wegovy) segment led the market with the largest revenue share of 60.70% in 2024, solidifying its position as the preferred treatment option for obesity management. Semaglutide's proven efficacy in significantly reducing body weight and improving metabolic health, and its growing clinical acceptance make it the leading therapy in this class.

  - Based on route of administration, the parenteral segment led the market with the largest revenue share of 92.7% in 2024. These injectable

+357 96 030922
info@marketpublishers.com

therapies, administered either weekly or bi-weekly, are preferred due t%li%their proven effectiveness in promoting long-term weight loss and addressing underlying metabolic conditions like insulin resistance.

Based on distribution channel, the retail pharmacies segment led the market with the largest revenue share of 55.46% in 2024. The growing convenience and accessibility offered by retail pharmacies made them the primary point of access for patients using weight loss medications.

North America accounted for the largest market share in 2024, attributed t%li%factors such as a well-established healthcare infrastructure, high awareness of neurological disorders, and the availability of advanced treatment options. The region's strong focus on research and innovation further supports market growth.

Contents

+357 96 030922
info@marketpublishers.com

CHAPTER 4. GLP-1 AGONISTS WEIGHT LOSS DRUGS MARKET: BY DRUG ESTIMATES & TREND ANALYSIS

CHAPTER 5. GLP-1 AGONISTS WEIGHT LOSS DRUGS MARKET: BY ROUTE OF ADMINISTRATION ESTIMATES & TREND ANALYSIS

CHAPTER 6. GLP-1 AGONISTS WEIGHT LOSS DRUGS MARKET: DISTRIBUTION CHANNEL ESTIMATES & TREND ANALYSIS

CHAPTER 7. GLP-1 AGONISTS WEIGHT LOSS DRUGS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS

+357 96 030922
info@marketpublishers.com

CHAPTER 8. COMPETITIVE LANDSCAPE

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: GLP-1 Agonists Weight Loss Drugs Market Size, Share & Trends Analysis By Drugs (Semaglutide (Wegovy), Tirzepatide (Zepbound)), By Route of Administration, By Distribution Channel, By Region, And Segment forecasts, 2025 - 2030

Product link: https://marketpublishers.com/r/G555FE952545EN.html

Price: US$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G555FE952545EN.html